Co-Diagnostics Q1 Revenue Declines

Ticker: CODX · Form: 10-Q · Filed: May 8, 2025 · CIK: 1692415

Co-Diagnostics, Inc. 10-Q Filing Summary
FieldDetail
CompanyCo-Diagnostics, Inc. (CODX)
Form Type10-Q
Filed DateMay 8, 2025
Risk Levelmedium
Sentimentbearish

Sentiment: bearish

Topics: revenue-decline, quarterly-report, medical-devices

TL;DR

CODX Q1 revenue down YoY, product revenue $1.75M vs $2.23M. Grant revenue also lower.

AI Summary

Co-Diagnostics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported product revenue of $1.75 million for Q1 2025, a decrease from $2.23 million in Q1 2024. Grant revenue also saw a decline, from $0.12 million in Q1 2024 to $0.08 million in Q1 2025. The company's total assets were $23.8 million as of March 31, 2025.

Why It Matters

The decline in revenue for Co-Diagnostics, Inc. in the first quarter of 2025 compared to the previous year may indicate challenges in product sales and grant funding, potentially impacting future growth and financial stability.

Risk Assessment

Risk Level: medium — The reported decrease in both product and grant revenue suggests potential financial headwinds for the company.

Key Numbers

  • $1.75M — Q1 2025 Product Revenue (Represents a decrease from Q1 2024)
  • $2.23M — Q1 2024 Product Revenue (Higher than Q1 2025 product revenue)
  • $0.08M — Q1 2025 Grant Revenue (Represents a decrease from Q1 2024)
  • $0.12M — Q1 2024 Grant Revenue (Higher than Q1 2025 grant revenue)
  • $23.8B — Total Assets (As of March 31, 2025)

Key Players & Entities

  • Co-Diagnostics, Inc. (company) — Filer of the 10-Q
  • March 31, 2025 (date) — End of reporting period
  • $1.75 million (dollar_amount) — Product revenue for Q1 2025
  • $2.23 million (dollar_amount) — Product revenue for Q1 2024
  • $0.12 million (dollar_amount) — Grant revenue for Q1 2024
  • $0.08 million (dollar_amount) — Grant revenue for Q1 2025
  • $23.8 million (dollar_amount) — Total assets as of March 31, 2025

FAQ

What was Co-Diagnostics, Inc.'s product revenue for the first quarter of 2025?

Co-Diagnostics, Inc.'s product revenue for the first quarter of 2025 was $1.75 million.

How does the Q1 2025 product revenue compare to Q1 2024?

The product revenue for Q1 2025 ($1.75 million) was lower than for Q1 2024 ($2.23 million).

What was the grant revenue for the first quarter of 2025?

The grant revenue for the first quarter of 2025 was $0.08 million.

How does the Q1 2025 grant revenue compare to Q1 2024?

The grant revenue for Q1 2025 ($0.08 million) was lower than for Q1 2024 ($0.12 million).

What were Co-Diagnostics, Inc.'s total assets as of March 31, 2025?

Co-Diagnostics, Inc.'s total assets as of March 31, 2025, were $23.8 million.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Co-Diagnostics, Inc. (CODX).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.